tldrdailynews.com logo

BMS claims Phase 2 success for GPRC5D-directed CAR-T in myeloma

1 min read
Source: Endpoints News
BMS claims Phase 2 success for GPRC5D-directed CAR-T in myeloma
Photo: Endpoints News
TL;DR Summary

Bristol Myers Squibb claims Phase 2 success for a GPRC5D-targeted CAR-T therapy in multiple myeloma, underscoring the potential of this target while noting ongoing questions about durability and outcomes after progression.

Topics:business#bristol-myers-squibb#car-t#cellgene-tx#gprc5d#multiple-myeloma#phase-2-trial
Share this article
  1. Bristol Myers claims Phase 2 success for GPRC5D-directed CAR-T  Endpoints News
  2. BMS’ pivotal CAR-T multiple myeloma trial hits primary endpoint  Fierce Biotech
  3. Bristol Myers' blood cancer cell therapy succeeds in mid-stage trial  Reuters
  4. Next-gen CAR-T from BMS passes pivotal test in quadruple-class exposed myeloma  FirstWord Pharma
  5. Arlo-Cel Meets ORR End Point in BCMA-Pretreated, Quadruple-Class Exposed R/R Myeloma  OncLive

Reading Insights

Total Reads

1

Unique Readers

5

Time Saved

2 min

vs 3 min read

Condensed

94%

527 → 31 words

Want the full story? Read the original article

Read on Endpoints News